Feature | April 16, 2014| Dave Fornell

Federal Court Orders Injunction on U.S. Sales of Medtronic CoreValve

Medtronic plans to appeal court ruling

Corevalve beats surgery, ACC 2014, TAVR vs surgery, Edwards lawsuit
April 16, 2014 — The U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system in the United States. The court ordered the injunction April 10, which will go into effect the Week of April 21. 
 
At Medtronic's request, the Federal District Court agreed to postpone the implementation of the order for seven business days to allow Medtronic to seek prompt relief from the Federal Circuit Court of Appeals. Medtronic is appealing the court's injunction, and intends to ask the Federal Circuit Court of Appeals to prevent it from going into effect until it determines if the injunction was properly issued. 
 
The decision stems from a federal jury decision in 2010 that CoreValve willfully infringed on patent use for the Edwards Lifesciences Corp. U.S. Andersen transcatheter aortic valve replacement patent. 
 
At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. The companies are to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve to make a clinical judgment as to which device to implant (CoreValve or the Edwards’ Sapien device) free from the limitations of the injunction. The court stated that CoreValve is a “safer device, and that patients in whom it is implanted have better outcomes with a lower risk of death.” 
 
Medtronic said the ruling has no impact on the sale or marketing of CoreValve outside of the United States or the use of CoreValve in the current U.S. clinical trials.
 
Edwards initiated this case in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In November 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision. In October 2013, the U.S. Supreme Court declined to hear Medtronic's appeal.
 
The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
 
The Edwards’ Sapien TAVR system was the first to gain U.S. Food and Drug Administration (FDA) clearance in November 2011. The Medtronic CoreValve gained FDA approval this past January as the second TAVR device on the U.S. market. Many observers view the lawsuits by Edwards as a way to prevent competition in the U.S. market, similar to the suits and counter suits involved with drug-eluting stent manufactures in the United States over the past decade. Edwards filed similar suits in Europe after both valves gained market clearance there. Those suits have been ongoing for years.
 
The CoreValve System received FDA approval in January for patients at extreme risk for surgical valve replacement. Prior to that date, CoreValve therapy was available to extreme risk patients who were eligible to participate in the U.S. clinical trial. The CoreValve System is not yet approved in the U.S. for other patient groups.
 
In clinical trial data, the CoreValve appears to have better outcomes than that of the Sapien valve. At the American College of Cardiology (ACC) annual meeting in March, late-breaking trial data stated that the CoreValve actually out-performed surgical valve replacement despite the inexperience of the CoreValve operators with the device. The CoreValve U.S. pivotal high-risk patient trial showed the Medtronic self-expanding CoreValve device had a 26 percent survival benefit above the surgical valve implant patients. In the same patient population, the Edwards Sapien was found to be equal to surgery, but was not superior to surgery.
 
For more information: www.edwards.com, www.medtronic.com
 

Related Content

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient.

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient. 

 

Feature | Heart Valve Technology | April 20, 2018 | Dave Fornell
While there is fear by many about the trend of hospitals consolidating into larger healthcare systems, one advantage
A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

Feature | Heart Valve Technology | April 19, 2018 | Dave Fornell
Patient selection for who is best suited for a ...
Videos | Heart Valve Technology | April 18, 2018
Northwestern Medicine has purchased several smaller Chicago suburban hospitals in the past few years to expand its he
University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement
News | Heart Valve Technology | April 06, 2018
University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the...
LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China
News | Heart Valve Technology | March 30, 2018
LivaNova PLC announced the first patient enrollment in the Perceval Valve Clinical study for Chinese Registration (“...
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
News | Heart Valve Technology | March 27, 2018
March 27, 2018 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Overlay Init